Rappel de Optipac Bone Cement

Selon Department of Health, Therapeutic Goods Administration, ce/cet/cette rappel concerne un dispositif en/au/aux/à Australia qui a été fabriqué par Zimmer Biomet Pty Ltd.

Qu'est-ce que c'est?

Une correction ou un retrait opéré par un fabricant afin de répondre à un problème causé par un dispositif médical. Les rappels surviennent lorsqu'un dispositif médical est défectueux, lorsqu'il pourrait poser un risque pour la santé, ou les deux à la fois.

En savoir plus sur les données ici
  • Type d'événement
  • ID de l'événement
  • Classe de risque de l'événement
    Class II
  • Date de mise en oeuvre de l'événement
  • Pays de l'événement
  • Source de l'événement
  • URL de la source de l'événement
  • Notes / Alertes
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Notes supplémentaires dans les données
  • Cause
    Through an internal investigation biomet orthopaedics has identified that the sterilisation process for optipac bone cement cannot be guaranteed to be fully compliant. the most probable potential risks related to this sterilisation issue include:- inflammation- pain- early infection- potential swelling around the jointbiomet orthopaedics conducted a review of complaints for the optipac and the reported rate for infections was 0.0004 %.
  • Action
    Zimmer Biomet is advising customers to immediately locate and remove affected devices, and then return these devices to Zimmer Biomet who will issue credit for returned stock. Zimmer is advising that, based on the current information, there does not appear to be a need for additional patient follow-up beyond the standard patient follow-up. This action has been closed-out on 25/05/2017.


  • Modèle / numéro de série
    Optipac Bone CementOptipac 40 Refobacin Plus Bone CementOptipac 60 Refobacin Plus Bone CementOptipac 80 Refobacin Plus Bone CementOptipac-S 40 Refobacin Plus Bone CementOptipac-S 60 Refobacin Plus Bone CementOptipac-S 80 Refobacin Plus Bone CementAll sizes manufactured since January 2014Multiple Material and Batch NumbersARTG Number: 168753
  • Manufacturer


  • Société-mère du fabricant (2017)
  • Commentaire du fabricant
    “The safety of patients has always been, and continues to be, Zimmer Biomet’s top priority and it is our honor to be a leader in this industry for the past 90 years,” Zimmer Biomet told ICIJ in a statement. “We adhere to strict regulatory standards, and work closely with the FDA and all applicable regulatory agencies in each of our regions as part of our commitment to operating a first-rate quality management system across our global manufacturing network. The company added that it is focused on staying at the forefront of innovation and doing right by the millions of patients who rely on the company’s products.
  • Source